CN104411706A - 咪唑酮类衍生物、其药物组合物和用途 - Google Patents

咪唑酮类衍生物、其药物组合物和用途 Download PDF

Info

Publication number
CN104411706A
CN104411706A CN201380034055.8A CN201380034055A CN104411706A CN 104411706 A CN104411706 A CN 104411706A CN 201380034055 A CN201380034055 A CN 201380034055A CN 104411706 A CN104411706 A CN 104411706A
Authority
CN
China
Prior art keywords
bases
quinoline
methyl
phenyl
imidazos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201380034055.8A
Other languages
English (en)
Other versions
CN104411706B (zh
Inventor
张兴民
王恩思
牛生秀
郭靖
戴琢琳
郑楠
杜镇建
季奇
李钦艳
梁铁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Forelandpharma Co ltd
Original Assignee
Beijing Forelandpharma Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Forelandpharma Co ltd filed Critical Beijing Forelandpharma Co ltd
Priority to CN201380034055.8A priority Critical patent/CN104411706B/zh
Publication of CN104411706A publication Critical patent/CN104411706A/zh
Application granted granted Critical
Publication of CN104411706B publication Critical patent/CN104411706B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本申请涉及咪唑酮类化合物、其药学可接受的盐、溶剂化物、多晶形物或前药，还涉及包含上述物质的药物组合物和用于预防和治疗蛋白激酶相关性疾病如癌症、代谢疾病、心血管疾病等的用途。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201380034055.8A 2012-11-20 2013-11-20 咪唑酮类衍生物、其药物组合物和用途 Active CN104411706B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201380034055.8A CN104411706B (zh) 2012-11-20 2013-11-20 咪唑酮类衍生物、其药物组合物和用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2012104707402 2012-11-20
CN201210470740.2A CN103833752A (zh) 2012-11-20 2012-11-20 咪唑酮并喹啉类衍生物、其药物组合物和用途
CN201380034055.8A CN104411706B (zh) 2012-11-20 2013-11-20 咪唑酮类衍生物、其药物组合物和用途
PCT/CN2013/087521 WO2014079364A1 (zh) 2012-11-20 2013-11-20 咪唑酮类衍生物、其药物组合物和用途

Publications (2)

Publication Number Publication Date
CN104411706A true CN104411706A (zh) 2015-03-11
CN104411706B CN104411706B (zh) 2016-11-16

Family

ID=50775545

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201210470740.2A Pending CN103833752A (zh) 2012-11-20 2012-11-20 咪唑酮并喹啉类衍生物、其药物组合物和用途
CN201380034055.8A Active CN104411706B (zh) 2012-11-20 2013-11-20 咪唑酮类衍生物、其药物组合物和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201210470740.2A Pending CN103833752A (zh) 2012-11-20 2012-11-20 咪唑酮并喹啉类衍生物、其药物组合物和用途

Country Status (2)

Country Link
CN (2) CN103833752A (zh)
WO (1) WO2014079364A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160264570A1 (en) * 2013-11-15 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method of blocking transmission of malarial parasite
CN104447740B (zh) * 2013-11-20 2017-02-22 北京富龙康泰生物技术有限公司 咪唑酮类衍生物、其药物组合物和用途
EP2915811A1 (en) * 2014-03-04 2015-09-09 Centre Régional de Lutte contre le Cancer - Centre François Baclesse MCL-1 modulating compounds for cancer treatment
CN108203404A (zh) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
CN108440514A (zh) * 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用
CN108558844A (zh) * 2018-05-16 2018-09-21 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108727354A (zh) * 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108440513A (zh) * 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108727355A (zh) * 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101616672A (zh) * 2007-02-20 2009-12-30 诺瓦提斯公司 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
CN102827160A (zh) * 2011-06-16 2012-12-19 上海阳帆医药科技有限公司 PI3K或PI3K/m-TOR通路抑制剂及其在药学中的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101616672A (zh) * 2007-02-20 2009-12-30 诺瓦提斯公司 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
CN102827160A (zh) * 2011-06-16 2012-12-19 上海阳帆医药科技有限公司 PI3K或PI3K/m-TOR通路抑制剂及其在药学中的用途

Also Published As

Publication number Publication date
CN103833752A (zh) 2014-06-04
WO2014079364A1 (zh) 2014-05-30
CN104411706B (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
CN104411706A (zh) 咪唑酮类衍生物、其药物组合物和用途
AU2016366694B2 (en) Methods for treating huntington's disease
JP7097358B2 (ja) アルファｖインテグリン阻害剤としての３－置換プロピオン酸
CA2660899C (en) Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
AU2011334624B2 (en) Substituted benzopyrazin derivatives as FGFR kinase inhibitors for the treatment of cancer diseases
RU2702906C2 (ru) Птеридины в качестве fgfr ингибиторов
CA2874911C (en) New compounds
CN112638917A (zh) 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
BR112017026392B1 (pt) Composto derivado tricíclico, método para sua preparação e seu uso
KR20110075010A (ko) 키나제 억제제로서 유용한 이미다조피리다진카르보니트릴
PT2419428E (pt) Derivados de imidazo[1,2-a]piridina como inibidores de fgfr quinase para utilização terapêutica
CN104341425B (zh) 氘代乙炔衍生物、其药物组合物及应用
BR112021001122A2 (pt) Composto, composição farmacêutica para a prevenção ou tratamento de câncer e composição farmacêutica para inibir a atividade de flt3 quinase
JP2020023554A (ja) ピリミジン化合物及びその医薬用途
CN102584830A (zh) 二氢化茚酰胺化合物、其药物组合物及其用途
CN109415341A (zh) 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
JP6290412B2 (ja) イミダゾロン系誘導体、その医薬組成物及び用途
WO2016208592A1 (ja) 二環性複素環アミド誘導体
KR20130036201A (ko) 헤타릴아미노나프티리딘
JP2018527412A (ja) Ｐｅｒｋ阻害剤としての１−フェニルピロリジン−２−オン誘導体
WO2012089106A1 (zh) 作为蛋白激酶抑制剂的芳炔类衍生物及其医疗用途
KR20200013718A (ko) 바닌 억제제로서의 헤테로방향족 화합물
CN103130791B (zh) 一种新型苯甲酰胺类化合物
JP2022504982A (ja) ＴＧＦ－βＲ１阻害剤としての化合物及びその応用
WO2014086102A1 (zh) 作为酪氨酸激酶抑制剂的吲哚满酮衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant